The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.
The European Commission has approved Novartis' gene therapy Itvisma (onasemnogene abeparvovec) for patients at least two years old with 5q-associated spinal muscular atrophy (SMA) and biallelic SMN1 ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
The firm will submit a rolling NDA to the agency in early 2027, containing data from the randomized, controlled EMPEROR trial.
The T2EVOLVE association cements the work of a temporary Innovative Medicines Initiative-funded project that began in 2021.
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
The firm is preparing to test a gene replacement therapy that uses an ultrasound-mediated strategy to deliver a full-length ...
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.
Innovent Biologics will commercialize Eli Lilly's CDK4/6 inhibitor Verzenio (abemaciclib) in mainland China, where it is called Verzenios, the companies announced Tuesday. Lilly will retain rights to ...
The acquisition will bring navtemadlin, Kartos' late-stage treatment program in myelofibrosis, to Ipsen's pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results